International Journal of Molecular Sciences the Potential Role of Kallistatin in the Development of Abdominal Aortic Aneurysm

Abdominal aortic aneurysm (AAA) is a vascular condition that causes permanent dilation of the abdominal aorta, which can lead to death due to aortic rupture. The only treatment for AAA is surgical repair, and there is no current drug treatment for AAA. Aortic inflammation, vascular smooth muscle cell apoptosis, angiogenesis, oxidative stress and vascular remodeling are implicated in AAA pathogenesis. Kallistatin is a serine proteinase inhibitor, which has been shown to have a variety of functions, potentially relevant in AAA pathogenesis. Kallistatin has been reported to have inhibitory effects on tumor necrosis factor alpha (TNF-α) signaling induced oxidative stress and apoptosis. Kallistatin also inhibits vascular endothelial growth factor (VEGF) and Wnt canonical signaling, which promote inflammation, angiogenesis, and vascular remodeling in various pre-clinical experimental models. This review explores the potential protective role of kallistatin in AAA pathogenesis.

[1]  J. Golledge,et al.  Modulation of Kinin B2 Receptor Signaling Controls Aortic Dilatation and Rupture in the Angiotensin II–Infused Apolipoprotein E–Deficient Mouse , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[2]  J. Golledge,et al.  Oxidative stress and abdominal aortic aneurysm: potential treatment targets. , 2016, Clinical science.

[3]  I. Yam,et al.  Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress. , 2016, Kidney international.

[4]  Jian-xing Ma,et al.  SERPINA3K Plays Antioxidant Roles in Cultured Pterygial Epithelial Cells through Regulating ROS System , 2014, PloS one.

[5]  L. Chao,et al.  Novel Role of Kallistatin in Vascular Repair by Promoting Mobility, Viability, and Function of Endothelial Progenitor Cells , 2014, Journal of the American Heart Association.

[6]  H. Yang,et al.  Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-κB signaling pathway. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  K. Sunagawa,et al.  Suppression of abdominal aortic aneurysm formation by inhibition of prolyl hydroxylase domain protein through attenuation of inflammation and extracellular matrix disruption. , 2014, Clinical science.

[8]  Y. Diao,et al.  Recombinant Human Kallistatin Inhibits Angiogenesis by Blocking VEGF Signaling Pathway , 2014, Journal of cellular biochemistry.

[9]  S. Spechler,et al.  Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. , 2014, Gastroenterology.

[10]  A. Jenkins,et al.  Elevated Circulation Levels of an Anti-angiogenic SERPIN in Patients with Diabetic Microvascular Complications Impairs Wound Healing through Suppression of Wnt Signaling , 2014, The Journal of investigative dermatology.

[11]  H. Jing,et al.  Quercetin reduces oxidative stress and inhibits activation of c-Jun N-terminal kinase/activator protein-1 signaling in an experimental mouse model of abdominal aortic aneurysm , 2013, Molecular medicine reports.

[12]  K. Zhou,et al.  Antiangiogenic and Antineuroinflammatory Effects of Kallistatin Through Interactions With the Canonical Wnt Pathway , 2013, Diabetes.

[13]  Jian-xing Ma,et al.  Regulation of endothelial progenitor cell release by Wnt signaling in bone marrow. , 2013, Investigative ophthalmology & visual science.

[14]  R. Bolli,et al.  Vascular endothelial growth factor in heart failure , 2013, Nature Reviews Cardiology.

[15]  L. Chao,et al.  Kallistatin Modulates Immune Cells and Confers Anti-Inflammatory Response To Protect Mice from Group A Streptococcal Infection , 2013, Antimicrobial Agents and Chemotherapy.

[16]  N. de Las Heras,et al.  Pathophysiology of Vascular Remodeling in Hypertension , 2013, International journal of hypertension.

[17]  Stefan Liebner,et al.  Wnt signaling in the vasculature. , 2013, Experimental cell research.

[18]  L. Chao,et al.  Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6 , 2013, Molecular and Cellular Biochemistry.

[19]  L. Chao,et al.  Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. , 2013, Metabolism: clinical and experimental.

[20]  Yasuhiro Kobayashi.  [Roles of Wnt signaling in bone metabolism]. , 2012, Clinical calcium.

[21]  Xianglin Shi,et al.  NADPH Oxidase 4 Mediates Insulin-Stimulated HIF-1α and VEGF Expression, and Angiogenesis In Vitro , 2012, PloS one.

[22]  L. Chao,et al.  Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. , 2012, American journal of physiology. Renal physiology.

[23]  J. Golledge,et al.  Current status of medical management for abdominal aortic aneurysm. , 2011, Atherosclerosis.

[24]  L. Chao,et al.  Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. , 2010, American journal of physiology. Heart and circulatory physiology.

[25]  L. Chao,et al.  Kallistatin Inhibits Vascular Inflammation by Antagonizing Tumor Necrosis Factor-&agr;-Induced Nuclear Factor &kgr;B Activation , 2010, Hypertension.

[26]  C. Crews,et al.  Activation of the planar cell polarity formin DAAM1 leads to inhibition of endothelial cell proliferation, migration, and angiogenesis , 2010, Proceedings of the National Academy of Sciences.

[27]  Lee Chao,et al.  Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. , 2010, American journal of physiology. Heart and circulatory physiology.

[28]  T. Haas,et al.  p38 MAPK activity is stimulated by vascular endothelial growth factor receptor 2 activation and is essential for shear stress‐induced angiogenesis , 2010, Journal of cellular physiology.

[29]  L. Chao,et al.  Kruppel-like Factor 4 Is a Novel Mediator of Kallistatin in Inhibiting Endothelial Inflammation via Increased Endothelial Nitric-oxide Synthase Expression* , 2009, The Journal of Biological Chemistry.

[30]  J. Golledge,et al.  A Systematic Review of Studies Examining Inflammation Associated Cytokines in Human Abdominal Aortic Aneurysm Samples , 2009, Disease markers.

[31]  L. Chao,et al.  Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction , 2008, Laboratory Investigation.

[32]  Maria F. Gomez,et al.  Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys? , 2008, Current opinion in lipidology.

[33]  W. Birchmeier,et al.  Wnt signalling and its impact on development and cancer , 2008, Nature Reviews Cancer.

[34]  L. Chao,et al.  Salutary Effect of Kallistatin in Salt-Induced Renal Injury, Inflammation, and Fibrosis via Antioxidative Stress , 2008, Hypertension.

[35]  F. Guadagni,et al.  Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. , 2007, In vivo.

[36]  C. Niehrs,et al.  Function and biological roles of the Dickkopf family of Wnt modulators , 2006, Oncogene.

[37]  U. Förstermann,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.

[38]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[39]  Yong Chul Lee.  The involvement of VEGF in endothelial permeability: a target for anti-inflammatory therapy. , 2005, Current opinion in investigational drugs.

[40]  A. Karsan,et al.  Roles of reactive oxygen species in angiopoietin‐1/tie‐2 receptor signaling , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Aoki,et al.  Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model , 2005, Gene Therapy.

[42]  L. Chao,et al.  Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. , 2005, Arthritis and rheumatism.

[43]  G. Bloom,et al.  IQGAP1, a Novel Vascular Endothelial Growth Factor Receptor Binding Protein, Is Involved in Reactive Oxygen Species–Dependent Endothelial Migration and Proliferation , 2004, Circulation research.

[44]  A. Koch,et al.  Vascular endothelium and immune responses: implications for inflammation and angiogenesis. , 2004, Rheumatic diseases clinics of North America.

[45]  M. Yen,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. , 2003, Molecular pharmacology.

[46]  Takahiro Doi,et al.  Tumor Necrosis Factor-α-induced IKK Phosphorylation of NF-κB p65 on Serine 536 Is Mediated through the TRAF2, TRAF5, and TAK1 Signaling Pathway* , 2003, Journal of Biological Chemistry.

[47]  P. Cirri,et al.  Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. , 2003, Trends in biochemical sciences.

[48]  L. Chao,et al.  Structural elements of kallistatin required for inhibition of angiogenesis. , 2003, American journal of physiology. Cell physiology.

[49]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[50]  G. Gao,et al.  Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage , 2003, Diabetologia.

[51]  Chad Johnson,et al.  Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. , 2002, Circulation research.

[52]  Lee Chao,et al.  Kallistatin is a new inhibitor of angiogenesis and tumor growth. , 2002, Blood.

[53]  I. Shiojima,et al.  Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.

[54]  D. Goeddel,et al.  TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. , 2002, Molecular cell.

[55]  T. Galeotti,et al.  Reactive Oxygen Species as Downstream Mediators of Angiogenic Signaling by Vascular Endothelial Growth Factor Receptor-2/KDR* , 2002, The Journal of Biological Chemistry.

[56]  W. Aird,et al.  Vascular endothelial growth factor induces manganese‐superoxide dismutase expression in endothelial cells by a Racl‐regulated NADPH oxidase‐dependent mechanism , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  L. Chao,et al.  Identification of a Major Heparin-binding Site in Kallistatin* , 2001, The Journal of Biological Chemistry.

[58]  J. Lambeth,et al.  Novel homologs of gp91phox. , 2000, Trends in biochemical sciences.

[59]  Shuibang Wang,et al.  Superoxide Production and Reactive Oxygen Species Signaling by Endothelial Nitric-oxide Synthase* , 2000, The Journal of Biological Chemistry.

[60]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[61]  M. Blanar,et al.  HCPTPA, a Protein Tyrosine Phosphatase That Regulates Vascular Endothelial Growth Factor Receptor-mediated Signal Transduction and Biological Activity* , 1999, The Journal of Biological Chemistry.

[62]  R. Busse,et al.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.

[63]  W. Sessa,et al.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt , 1999, Nature.

[64]  G. Majno.  Chronic inflammation: links with angiogenesis and wound healing. , 1998, The American journal of pathology.

[65]  S. Soker,et al.  Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[66]  K. Alitalo,et al.  Proinflammatory Cytokines Regulate Expression of the Lymphatic Endothelial Mitogen Vascular Endothelial Growth Factor-C* , 1998, The Journal of Biological Chemistry.

[67]  L. Chao,et al.  Kallistatin in blood pressure regulation transgenic and somatic gene delivery studies. , 1997, Trends in cardiovascular medicine.

[68]  Jacques Landry,et al.  p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells , 1997, Oncogene.

[69]  D. Willoughby,et al.  The codependence of angiogenesis and chronic inflammation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  L. Chao,et al.  Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. , 1997, Human gene therapy.

[71]  B. Hemmings.  Akt Signaling--Linking Membrane Events to Life and Death Decisions , 1997, Science.

[72]  Y. Liang,et al.  Tissue Kallikrein-binding Protein Reduces Blood Pressure in Transgenic Mice* , 1996, The Journal of Biological Chemistry.

[73]  L. Chao,et al.  Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. , 1996, The American journal of physiology.

[74]  R. Sayers,et al.  Angiogenesis in abdominal aortic aneurysms. , 1996, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[75]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[76]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. , 1995, International archives of allergy and immunology.

[77]  V. Panagia,et al.  Receptor-mediated signalling pathways acting through hydrolysis of membrane phospholipids in cardiomyocytes. , 1993, Cardioscience.

[78]  Yasuhiro Kobayashi,et al.  Roles of Wnt signals in bone resorption during physiological and pathological states , 2012, Journal of Molecular Medicine.

[79]  Jiahuai Han,et al.  Activation and signaling of the p38 MAP kinase pathway , 2005, Cell Research.

[80]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[81]  G. Firestein,et al.  Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. , 1999, The Journal of clinical investigation.

[82]  K. Plate,et al.  Differentiation of the brain vasculature: the answer came blowing by the Wnt , 2010, Journal of angiogenesis research.